{"id":"medical-standard-of-care-for-itp","safety":{"commonSideEffects":[{"rate":null,"effect":"Infection"},{"rate":null,"effect":"Bleeding"},{"rate":null,"effect":"Thrombosis (with TPO-RAs)"},{"rate":null,"effect":"Hyperglycemia (with corticosteroids)"}]},"_chembl":null,"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"Medical standard of care for ITP generally includes corticosteroids as first-line therapy to suppress the immune system's attack on platelets, often combined with intravenous immunoglobulin (IVIG) or anti-D immunoglobulin in acute cases. For chronic ITP, thrombopoietin receptor agonists (TPO-RAs) are commonly used to stimulate megakaryocyte development and platelet production. The specific mechanism depends on which standard-of-care agent is being evaluated in the phase 3 trial.","oneSentence":"This represents the established standard treatment approach for immune thrombocytopenia (ITP), which typically aims to increase platelet counts through immune modulation or platelet production stimulation.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T01:20:32.160Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Immune thrombocytopenia (ITP)"}]},"trialDetails":[{"nctId":"NCT07426107","phase":"","title":"Development and Prospective Validation of an AI Model for Prognosis in ITP Patients Undergoing Coronary Revascularization","status":"NOT_YET_RECRUITING","sponsor":"Xiao Hui Zhang","startDate":"2026-02-25","conditions":"Immune Thrombocytopenic Purpura, Coronary Artery Disease","enrollment":600},{"nctId":"NCT07310342","phase":"NA","title":"Physical Fitness of Children, Adolescents and Young Adults With Immune Thrombocytopenic Purpura","status":"NOT_YET_RECRUITING","sponsor":"University Hospital, Bordeaux","startDate":"2025-12-15","conditions":"Immune Thrombocytopenic Purpura","enrollment":53},{"nctId":"NCT00415532","phase":"PHASE3","title":"Romiplostim (AMG 531) Versus Medical Standard of Care for Immune (Idiopathic) Thrombocytopenic Purpura","status":"COMPLETED","sponsor":"Amgen","startDate":"2006-12-01","conditions":"Idiopathic Thrombocytopenic Purpura, Thrombocytopenia, Thrombocytopenia in Subjects With Immune (Idiopathic) Thrombocytopenic Purpura (ITP)","enrollment":234}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":48,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_3","status":"active","brandName":"Medical Standard of Care for ITP","genericName":"Medical Standard of Care for ITP","companyName":"Amgen","companyId":"amgen","modality":"Small molecule","firstApprovalDate":"","aiSummary":"This represents the established standard treatment approach for immune thrombocytopenia (ITP), which typically aims to increase platelet counts through immune modulation or platelet production stimulation. Used for Immune thrombocytopenia (ITP).","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":1},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}